BioMarin Looks To Offload Roctavian As Gene Therapy’s Sales Drop

 
• By Alaric DeArment
  
BioMarin said it would divest Roctavian, its gene therapy for hemophilia A. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies